Condition: Recurrent Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-cell Lymphoma · Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd
This trial is a phase I clinical trial aimed at the safety and tolerability of RC19D2 cell injection in the treatment of CD19 positive patients with recurrent or refractory diffuse large B-cell lymphoma
This description comes directly from the study's public registry record.
lugui Qiu, MD · 13821266636 · qiulg@ihcams.ac.cn
dehui Zou, MD · 13602100955 · zoudehui@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Hematology Hospital of the Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06047197